Mac-2 结合蛋白糖基化异构体作为伴有持续病毒学应答的肝细胞癌的预后标志物。

Mac-2 Binding Protein Glycosylation Isomer as a Prognostic Marker for Hepatocellular Carcinoma With Sustained Virological Response.

机构信息

Division of Hepatobiliary and Pancreatic Surgery, Department of General Surgery, Graduate School of Medicine, Gunma University, Maebashi, Japan

Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

出版信息

Anticancer Res. 2022 Jan;42(1):245-251. doi: 10.21873/anticanres.15479.

DOI:10.21873/anticanres.15479

PMID:34969731

Abstract

BACKGROUND/AIM: Mac2-binding protein glycosylation isomer (M2BPGi) is a non-invasive marker for assessing liver fibrosis. This was a retrospective study investigating whether M2BPGi predicts recurrence of hepatocellular carcinoma (HCC) after hepatectomy in patients with HCC who achieved a sustained virological response (SVR).

PATIENTS AND METHODS

We retrospectively reviewed the clinicopathological factors from 60 patients who underwent hepatectomy for HCC after achieving a SVR. We divided all patients into high M2BPGi and low M2BPGi groups and analyzed the clinicopathological and surgical outcomes.

RESULTS

High M2BPGi (>1.54, n=23) was significantly associated with lower serum albumin, higher ICGR15, higher Fib-4 index, large blood loss, and worse recurrence-free survival compared to low M2BPGi (≤1.54, n=37). Multivariate analysis identified high M2BPGi and large tumor size as being associated with reduced recurrence-free survival. Multivariate analysis identified lower serum albumin, larger tumor size and higher DCP as associated with reduced overall survival. There was no difference regarding recurrence pattern.

CONCLUSION

Preoperative M2BPGi is a useful biomarker for HCC recurrence after hepatectomy for SVR-HCC.

摘要

背景/目的：M2BPGi 糖基化异构体是一种评估肝纤维化的非侵入性标志物。本研究为回顾性研究，旨在探讨 M2BPGi 是否可预测获得持续病毒学应答（SVR）的 HCC 患者行肝切除术后 HCC 复发。

患者和方法

我们回顾性分析了 60 例 SVR 后行肝切除术的 HCC 患者的临床病理因素。我们将所有患者分为高 M2BPGi 组（>1.54，n=23）和低 M2BPGi 组（≤1.54，n=37），并分析了临床病理和手术结局。

结果

与低 M2BPGi 组相比，高 M2BPGi 组（>1.54，n=23）的血清白蛋白较低、ICGR15 较高、Fib-4 指数较高、出血量较大，且无复发生存率较低。多因素分析表明，高 M2BPGi 和大肿瘤直径与无复发生存率降低相关。多因素分析表明，低血清白蛋白、大肿瘤直径和高 DCP 与总生存率降低相关。两组的复发模式无差异。